We are monitoring the impact of COVID-19 on Prostate Cancer Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1536
Share on
Share on

Global Prostate Cancer Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Diagnostic Techniques, Chemotherapy and Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1536
Pages: 175

Global Prostate Cancer Market Size (2021 to 2026)

As per our report, the global prostate cancer market size is projected to be worth USD 99.20 billion by 2026 and USD 63.02 billion in 2021, growing at a CAGR of 9.5% during the forecast period.

The prostate cancer market has a high demand for novel drugs that concentrate on unmet needs, such as improved survival time, less toxicity, better progression-free survival, improved effectiveness, and lesser cost. Prostate cancer is a prostate cancer progression, a gland present in the male reproductive system. The cancer cells might reach the other parts of the body, viz. the bones and lymph nodes from the prostate. In the later stages of cancer, it can cause urination, blood in the urine, etc. Prostate cancer is most of the time diagnosed by biopsy.

MARKET DRIVERS:

A few of the significant factors driving the growth of the global prostate cancer market include an increase in the prevalence of prostate cancer, increasing public awareness of prostate cancer therapy, greater R&D investment by drug developers, strong upcoming pipeline medicines, and the availability of novel prostate cancer treatments.

Although the specific cause of prostate cancer is unknown, overweight, obesity and any other tumorous development history are all risk factors. Even people with cardiovascular problems are susceptible to cancer metastases. As a result, all these are the factors driving the market expansion. In the male population, prostate cancer is the second most prevalent kind of cancer. Prostate cancer is more frequent in the senior population, and the world's population is expected to age, driving the market growth. Altering lifestyle, technological advancements in researching for new techniques to fight prostate cancer, increase in the funding in both the public and private sectors in drug advancement are some of the key reasons driving the growth of the global prostate cancer market.

The prostate cancer market is further anticipated to expand during the forecast period due to growth opportunities such as untapped market potential due to unmet medical treatment requirements, growing awareness among people, and advancements in the healthcare field. Further, patent expiration of significant drugs like Zytiga will likely provide lucrative opportunities during the forecast period.

Growth is expected to be fueled by the use of innovative technologies in screening and diagnostic testing. Multiparametric MRI (MP-MRI) can greatly enhance tumor identification while also confirming whether tissue biopsy is required. Due to the expiry of patents on key current products throughout the forecast period, several generic goods are anticipated to join the market. As a result, growth is expected to be fueled by these reasons. Other factors that contribute to the market's growth include an increase in demand for prostate cancer therapy and care and an increase in the use of hormonal drugs in non-metastatic castration-resistant and metastatic hormone naive prostate cancer situations. Furthermore, the developing nations' untapped potential offers attractive opportunities for market expansion.

MARKET RESTRAINTS:

The major restraints that challenge the growth of the global prostate cancer market are ever-changing reimbursement policies, extending the time span of treatment, the expensive nature of combination therapies, and managing the life cycle of drugs. In addition, the shortage of skilled people in monitoring the equipment in laboratories is slowly degrading the market demand. Besides, government bodies' frequent changes in economic strategies are hindering the market's growth rate.

The market's growth is projected to be restricted by extended treatment times and low demand for prostate cancer treatment medicines in developing nations. The market is also likely to be limited by the high cost of prostate cancer medicines and the low success rate of clinical trials. The high expenses of a tissue biopsy, especially during the advanced stages of a tumor, and medical consultation fees, are predicted to limit growth. Furthermore, issues such as inadequate reimbursement of treatment expenses may have a negative impact on the adoption rate of treatment techniques.

Impact of COVID-19 on the global prostate cancer market:

The coronavirus (COVID-19) pandemic has disrupted the world and has affected almost every sector in every corner. The crisis has additionally added an excess layer of pressure or burden in many people. Treating patients efficiently over the pandemic crisis has become a significant challenge for clinicians. Prostate cancer patients are at mounting risk of coronavirus infection along with illness and deaths if infected. Prostate cancer services are on hold due to the changing medical and surgical importance. Once accurately organized and to reduce the spread of the virus, prostate cancer patients can observe telemedicine, establish lifestyle changes, and maintain social distancing. Prostate cancer patients need to be followed up remotely unless and until the COVID 19 pandemic sets right. Prostate cancer patients have amplified occurrences and mortality from COVID 19 infection due to gender, age, and propensity factors.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Diagnostic Techniques, Surgery, Radiation Therapy, Chemotherapy and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global prostate cancer market has been segmented and sub-segmented based on diagnostic techniques, surgery, radiation therapy, chemotherapy, and region.

Prostate Cancer Market – By Diagnostic Techniques:

  • Digital Rectal Exam (DRE)
  • Prostate-Specific Antigen Test (PSA)

Based on the diagnostic techniques, the Prostate-Specific Antigen Test (PSA) segment is expected to grow rapidly during the forecast period. The PSA test is to diminish the possibility of death from cancer. The amplifying research and development activities are accompanying the booming ubiquity of castrate-resistant prostate cancer. The factors mentioned above foster market growth.

Prostate cancer is one of the most common cancers diagnosed amongst men aging over 45 years. The success rate of the treatment regimen is increased by timely screening and early diagnosis using PSA and DRE. The governments of industrialized nations are making efforts to organize and execute initiatives to raise awareness of screening tests for male patients over 50 years old, such as Prostate-Specific Antigen blood tests and Digital Rectal Exams (DRE). Prostate Cancer Canada was founded to assist prostate cancer research, treatment, and prevention.

Prostate Cancer Market – By Surgery:

  • Radical Prostatectomy
  • Orchidectomy
  • Trans Urethral Resection (TUR)

Based on surgery, A radical prostatectomy is the most common kind of prostate cancer surgery. The surgeon removes the whole prostate gland and some surrounding tissue, including the seminal vesicles, during this operation. The prostate gland and surrounding tissues are removed during radical prostatectomy. The seminal vesicles and several surrounding lymph nodes are frequently included. Prostate cancer that is localized to the prostate can be cured by radical prostatectomy.

Prostate Cancer Market – By Radiation Therapy:

  • External Beam Radiation Therapy
    • 3D Conformal Radiation Therapy
    • Intensity Modulated Radiation Therapy
    • Stereotactic Body Radiation Therapy
    • Proton Beam Radiation Therapy
  • Brachytherapy
    • Permanent Brachytherapy
    • Temporary Brachytherapy

Based on radiation therapy, the most frequent kind of radiation treatment is external-beam radiation therapy. The radiation oncologist uses equipment outside the body to focus a beam of x-rays on the cancer area. Radiation therapy for prostate cancer includes destroying tumors with high-energy beams or radioactive seeds. Brachytherapy, Intensity Modulated Radiation Therapy (IMRT), stereotactic radiosurgery, and proton therapy are the most frequent treatments we prescribe for prostate cancer.

Prostate Cancer Market – By Chemotherapy:

  • Docetaxel
  • Etoposide
  • Vinblastine
  • Carboplatin
  • Vinorelbine

Based on the chemotherapy, Docetaxel, the most frequent chemotherapy treatment for prostate cancer, is commonly used with prednisone, a steroid medication. Many men report improvements in disease-related symptoms such as pain, fatigue, and energy loss after starting docetaxel.

Prostate Cancer Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, the North American market segment has contributed a prominent share in recent years and is expected to grow exponentially during the forecast period. North America dominated the worldwide market in 2020, accounting for the highest sales share. The major causes for North America's market domination are the rising prevalence and high death rate of prostate cancer in the United States. In addition, this region is seeing a lot of money invested in R&D to create novel immunotherapy and targeted pharmacological treatments to treat these cancers.

The Asia Pacific is ruling the prostate cancer market due to factors such as increasing economies of the developing nations, rising youth population, rising prostate cancer cases in older people, increasing focus on the promotion of preventive drugs and research initiatives. Due to rising awareness of prostate cancer treatment and acceptance of prostate cancer treatment products, Asia-Pacific provides attractive opportunities for major prostate cancer treatment market players. Furthermore, advances in healthcare infrastructure, an increase in the number of hospitals with sophisticated medical facilities, a growing R&D sector, increased healthcare reforms, and technical advancements in healthcare all contribute to market growth.

Latin American regions are estimated to record the highest CAGR during the forecast period.

KEY MARKET PARTICIPANTS:

Prominent companies dominating the global prostate cancer market profiled in the report are Sanofi S.A., GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech.

RECENT MARKET DEVELOPMENTS:

  • Pfizer Company completed the Array Biopharma acquisition in June 2019; Pfizer is looking forward to expanding its product portfolio and research operations regarding prostate cancer with the biotech giant Array Biopharma.
  • In September 2019, The National Institute of Health had revealed that prostate cancer screens might turn to biomarkers in semen. Therefore, the edible and hub have collaborated to research extracellular miRNAs. As the research outcomes, they concluded that semen exosome miRNA-based biomarkers could improve the diagnosis of prostate cancer. 
  • Johnson and Johnson's company has developed a drug called Erleada for treating metastatic hormone-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer, which has got approved by the FDA in February 2018.
  • A company based in the U.K has launched a new advanced ultrasound imaging technique in 2018; the technique is integrated with artificial intelligence to enhance prostate cancer detection.
  • Mayroy SA Company demerged from Ispen Company in December 2019. 
  • In 2019, Profound Medical Inc. developed a TULSA tool (MRI-guided transurethral ultrasound ablation) for treating prostate cancer and enlarged prostate at high accuracy without any side effects.
  • Prostate cancer can be diagnosed accurately more shortly and simply by conducting urine tests at home, and this was confirmed by the Pilot Study, which has been conducted very recently.

1.Introduction                  

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods           

                1.4 General Study Assumptions

2. Research Methodology                           

                2.1 Introduction              

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

3. Overview                      

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 Epidemology             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                      

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market

5. Market Segmentation                              

                5.1 Diagnostic Techniques           

                                5.1.1 Introduction

                                5.1.2 Digital Rectal Exam (DRE)

                                5.1.3 Prostate Specific Antigen Test (PSA)

                                5.1.4 Y-o-Y Growth Analysis, By Product

                                5.1.5 Market Attractiveness Analysis, By Product

                                5.1.6 Market Share Analysis, By Product

                5.2 Surgery        

                                5.2.1 Introduction

                                5.2.2 Radical Prostatectomy

                                5.2.3 Orchidectomy

                                5.2.4 Trans Urethral Resection (TUR)

                                5.2.5 Y-o-Y Growth Analysis, By Type

                                5.2.6 Market Attractiveness Analysis, By Type

                                5.2.7 Market Share Analysis, By Type

                5.3 Radiation Therapy   

                                5.3.1 Introduction

                                5.3.2 External Beam Radiation Therapy

                                5.3.3 Brachytherapy

                                5.3.4 Y-o-Y Growth Analysis, By Application

                                5.3.5 Market Attractiveness Analysis, By Application

                                5.3.6 Market Share Analysis, By Application

                5.4 Chemotherapy         

                                5.4.1 Introduction

                                5.4.2 Docetaxel

                                5.4.3 Etoposide

                                5.4.4 Vinblastine

                                5.4.5 Carboplatin

                                5.4.6 Vinorelbine

                                5.4.7 Y-o-Y Growth Analysis, By Disease Indications

                                5.4.8 Market Attractiveness Analysis, By Disease Indications

                                5.4.9 Market Share Analysis, By Disease Indications

6. Geographical Analysis                              

                6.1 Introduction              

                                6.1.1 Regional Trends

                                6.1.2 Impact Analysis

                                6.1.3 Y-o-Y Growth Analysis

                                6.1.4 Market Attractiveness Analysis

                                6.1.5 Market Share Analysis               

                6.2 North America          

                                6.1.1 Introduction

                                6.1.2 United States

                                6.1.3 Canada 

                6.3 Europe         

                                6.2.1 Introduction

                                6.2.2 U.K

                                6.2.3 Spain

                                6.2.4 Germany

                                6.2.5 Italy 

                                6.2.6 France

                6.4 Asia-Pacific 

                                6.3.1 Introduction

                                6.3.2 China 

                                6.3.3 India 

                                6.3.4 Japan 

                                6.3.5 Australia

                                6.3.6 South Korea

                6.5 Latin America            

                                6.4.1 Introduction

                                6.4.2 Brazil

                                6.4.3 Argentina

                                6.4.4 Mexico

                                6.4.5 Rest of Latin America

                6.6 Middle East & Africa

                                6.5.1 Introduction

                                6.5.2 Middle-East

                                6.5.3 Africa

7.Strategic Analysis                        

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

8.Market Leaders' Analysis                          

                8.1 Sanofi S.A    

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Financial analysis

                                8.1.4 Recent Developments

                                8.1.5 SWOT analysis

                                8.1.6 Analyst View

                8.2 GlaxoSmithKline      

                8.3 AstraZeneca

                8.4 AbbVie         

                8.5 Varian Medical Systems        

                8.6 Elekta           

                8.7 Theragenics

                8.8 Pfizer            

                8.9 Novartis       

9.Competitive Landscape                            

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis        

                9.3 Agreements, collaborations and Joint Ventures          

                9.4 New Product Launches          

10.Market Outlook and Investment Opportunities                           

Appendix                           

                a) List of Tables

                b) List of Figures              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Prostate Cancer Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  3. Global Digital Rectal Exam (DRE) Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Prostate Specific Antigen Test (PSA) Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  6. Global Radical Prostatectomy Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Orchidectomy Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Trans Urethral Resection (TUR) Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  10. Global External Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  12. Global Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  13. Global Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Etoposide Market, By Region, From 2021 to 2026 (USD Million)
  15. Global Vinblastine Market, By Region, From 2021 to 2026 (USD Million)
  16. Global Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  17. Global Vinorelbine Market, By Region, From 2021 to 2026 (USD Million)
  18. Global Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  19. Global 3D Conformal Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  20. Global Intensity Modulated Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  21. Global Stereotactic Body Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  22. Global Proton Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  23. Global Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  24. Global Permanent Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  25. Global Temporary Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  26. North America Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  27. North America Digital Rectal Exam (DRE) Market, By Region, From 2021 to 2026 (USD Million)
  28. North America Prostate Specific Antigen Test (PSA) Market, By Region, From 2021 to 2026 (USD Million)
  29. North America Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  30. North America Radical Prostatectomy Market, By Region, From 2021 to 2026 (USD Million)
  31. North America Orchidectomy Market, By Region, From 2021 to 2026 (USD Million)
  32. North America Trans Urethral Resection (TUR) Market, By Region, From 2021 to 2026 (USD Million)
  33. North America Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  34. North America External Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  35. North America Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  36. North America Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  37. North America Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  38. North America Etoposide Market, By Region, From 2021 to 2026 (USD Million)
  39. North America Vinblastine Market, By Region, From 2021 to 2026 (USD Million)
  40. North America Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  41. North America Vinorelbine Market, By Region, From 2021 to 2026 (USD Million)
  42. United States Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  43. United States Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  44. United States Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  45. United States Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  46. Canada Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  47. Canada Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  48. Canada Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  49. Canada Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  50. North America Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  51. North America 3D Conformal Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  52. North America Intensity Modulated Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  53. North America Stereotactic Body Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  54. North America Proton Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  55. United States Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  56. Canada Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  57. North America Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  58. North America Permanent Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  59. North America Temporary Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  60. United States Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  61. Canada Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  62. Europe Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  63. Europe Digital Rectal Exam (DRE) Market, By Region, From 2021 to 2026 (USD Million)
  64. Europe Prostate Specific Antigen Test (PSA) Market, By Region, From 2021 to 2026 (USD Million)
  65. Europe Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  66. Europe Radical Prostatectomy Market, By Region, From 2021 to 2026 (USD Million)
  67. Europe Orchidectomy Market, By Region, From 2021 to 2026 (USD Million)
  68. Europe Trans Urethral Resection (TUR) Market, By Region, From 2021 to 2026 (USD Million)
  69. Europe Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  70. Europe External Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  71. Europe Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  72. Europe Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  73. Europe Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  74. Europe Etoposide Market, By Region, From 2021 to 2026 (USD Million)
  75. Europe Vinblastine Market, By Region, From 2021 to 2026 (USD Million)
  76. Europe Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  77. Europe Vinorelbine Market, By Region, From 2021 to 2026 (USD Million)
  78. U.K. Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  79. U.K. Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  80. U.K. Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  81. U.K. Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  82. Germany Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  83. Germany Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  84. Germany Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  85. Germany Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  86. France Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  87. France Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  88. France Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  89. France Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  90. Italy Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  91. Italy Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  92. Italy Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  93. Italy Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  94. Spain Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  95. Spain Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  96. Spain Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  97. Spain Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  98. Europe Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  99. Europe 3D Conformal Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  100. Europe Intensity Modulated Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  101. Europe Stereotactic Body Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  102. Europe Proton Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  103. U.K. Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  104. Germany Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  105. France Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  106. Italy Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  107. Spain Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  108. Europe Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  109. Europe Permanent Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  110. Europe Temporary Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  111. U.K. Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  112. Germany Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  113. France Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  114. Italy Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  115. Spain Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  116. Asia-Pacific Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  117. Asia-Pacific Digital Rectal Exam (DRE) Market, By Region, From 2021 to 2026 (USD Million)
  118. Asia-Pacific Prostate Specific Antigen Test (PSA) Market, By Region, From 2021 to 2026 (USD Million)
  119. Asia-Pacific Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  120. Asia-Pacific Radical Prostatectomy Market, By Region, From 2021 to 2026 (USD Million)
  121. Asia-Pacific Orchidectomy Market, By Region, From 2021 to 2026 (USD Million)
  122. Asia-Pacific Trans Urethral Resection (TUR) Market, By Region, From 2021 to 2026 (USD Million)
  123. Asia-Pacific Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  124. Asia-Pacific External Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  125. Asia-Pacific Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  126. Asia-Pacific Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  127. Asia-Pacific Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  128. Asia-Pacific Etoposide Market, By Region, From 2021 to 2026 (USD Million)
  129. Asia-Pacific Vinblastine Market, By Region, From 2021 to 2026 (USD Million)
  130. Asia-Pacific Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  131. Asia-Pacific Vinorelbine Market, By Region, From 2021 to 2026 (USD Million)
  132. Japan Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  133. Japan Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  134. Japan Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  135. Japan Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  136. China Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  137. China Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  138. China Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  139. China Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  140. India Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  141. India Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  142. India Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  143. India Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  144. Australia Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  145. Australia Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  146. Australia Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  147. Australia Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  148. South Korea Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  149. South Korea Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  150. South Korea Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  151. South Korea Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  152. Asia-Pacific Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  153. Asia-Pacific 3D Conformal Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  154. Asia-Pacific Intensity Modulated Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  155. Asia-Pacific Stereotactic Body Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  156. Asia-Pacific Proton Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  157. Japan Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  158. China Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  159. India Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  160. Australia Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  161. Asia-Pacific Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  162. Asia-Pacific Permanent Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  163. Asia-Pacific Temporary Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  164. Japan Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  165. China Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  166. India Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  167. Australia Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  168. Latin America Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  169. Latin America Digital Rectal Exam (DRE) Market, By Region, From 2021 to 2026 (USD Million)
  170. Latin America Prostate Specific Antigen Test (PSA) Market, By Region, From 2021 to 2026 (USD Million)
  171. Latin America Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  172. Latin America Radical Prostatectomy Market, By Region, From 2021 to 2026 (USD Million)
  173. Latin America Orchidectomy Market, By Region, From 2021 to 2026 (USD Million)
  174. Latin America Trans Urethral Resection (TUR) Market, By Region, From 2021 to 2026 (USD Million)
  175. Latin America Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  176. Latin America External Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  177. Latin America Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  178. Latin America Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  179. Latin America Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  180. Latin America Etoposide Market, By Region, From 2021 to 2026 (USD Million)
  181. Latin America Vinblastine Market, By Region, From 2021 to 2026 (USD Million)
  182. Latin America Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  183. Latin America Vinorelbine Market, By Region, From 2021 to 2026 (USD Million)
  184. Brazil Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  185. Brazil Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  186. Brazil Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  187. Brazil Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  188. Argentina Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  189. Argentina Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  190. Argentina Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  191. Argentina Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  192. Mexico Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  193. Mexico Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  194. Mexico Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  195. Mexico Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  196. Rest of Latin America Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  197. Rest of Latin America Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  198. Rest of Latin America Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  199. Rest of Latin America Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  200. Latin America Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  201. Latin America 3D Conformal Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  202. Latin America Intensity Modulated Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  203. Latin America Stereotactic Body Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  204. Latin America Proton Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  205. Brazil Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  206. Argentina Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  207. Mexico Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  208. Latin America Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  209. Latin America Permanent Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  210. Latin America Temporary Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  211. Brazil Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  212. Argentina Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  213. Mexico Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  214. Middle East & Africa Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  215. Middle East & Africa Digital Rectal Exam (DRE) Market, By Region, From 2021 to 2026 (USD Million)
  216. Middle East & Africa Prostate Specific Antigen Test (PSA) Market, By Region, From 2021 to 2026 (USD Million)
  217. Middle East & Africa Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  218. Middle East & Africa Radical Prostatectomy Market, By Region, From 2021 to 2026 (USD Million)
  219. Middle East & Africa Orchidectomy Market, By Region, From 2021 to 2026 (USD Million)
  220. Middle East & Africa Trans Urethral Resection (TUR) Market, By Region, From 2021 to 2026 (USD Million)
  221. Middle East & Africa Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  222. Middle East & Africa External Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  223. Middle East & Africa Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  224. Middle East & Africa Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  225. Middle East & Africa Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  226. Middle East & Africa Etoposide Market, By Region, From 2021 to 2026 (USD Million)
  227. Middle East & Africa Vinblastine Market, By Region, From 2021 to 2026 (USD Million)
  228. Middle East & Africa Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  229. Middle East & Africa Vinorelbine Market, By Region, From 2021 to 2026 (USD Million)
  230. Middle East Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  231. Middle East Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  232. Middle East Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  233. Middle East Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  234. Africa Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  235. Africa Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  236. Africa Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  237. Africa Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  238. Middle East & Africa Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  239. Middle East & Africa 3D Conformal Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  240. Middle East & Africa Intensity Modulated Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  241. Middle East & Africa Stereotactic Body Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  242. Middle East & Africa Proton Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  243. Middle East Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  244. Africa Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  245. Middle East & Africa Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  246. Middle East & Africa Permanent Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  247. Middle East & Africa Temporary Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  248. Middle East Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  249. Africa Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample